Back to top

Teva Buy Rating Reiterated as Pipeline Upside Supports Unchanged $42 Price Target

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Teva Pharmaceutical, with a price target of $42.00. Ashwani Verma has...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Teva Pharmaceutical Industries Ltd. (TEVA)